Overview of Tomapyrin

Quick Facts

Property	Description
Active Ingredients	Acetylsalicylic acid (ASA), Paracetamol, Caffeine
Form	Tablet (Oral)
Pharmacological Class	Combination Analgesic, Antipyretic, NSAID Derivative
General Purpose	Relief of pain and fever
Origin	Synthetic (Chemically Derived)

What Type of Medicine is Tomapyrin?

Tomapyrin is classified as a fixed-dose combination analgesic and antipyretic administered via the oral route, typically supplied as an immediate-release tablet. It is a synthetic medicinal entity composed of three distinct active compounds, distinguishing it from preparations that contain only a single agent. The overall drug is classified as a non-opioid analgesic combination, with the primary component, Acetylsalicylic acid (ASA), categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID) derivative. This three-way composition is intended for the management of discomfort, a characteristic that supports its use in cases like acute tension headaches.

Composition and Pharmaceutical Form

The drug’s core identity is defined by its three active ingredients: Acetylsalicylic acid (ASA), Paracetamol (also known as Acetaminophen), and Caffeine. This formulation is synthesized within a solid excipient base, common for oral tablet preparations. The pharmaceutical strategy involves combining the anti-inflammatory and analgesic properties of ASA, the antipyretic and analgesic action of Paracetamol, and the adjuvant, stimulating effect of Caffeine. Paracetamol itself is an established analgesic and antipyretic agent. This inclusion confirms that this medicine's components are considered fundamental for pain and fever management.

General Purpose and Benefit of the Combination

The general purpose of Tomapyrin is to achieve an accelerated and robust therapeutic action for the relief of general discomfort, focusing on reducing both pain and elevated body temperature. The triple-ingredient composition is intentionally formulated to create an enhanced therapeutic action; the addition of Caffeine serves to boost and accelerate the pain-relieving efficacy of the primary components, ASA and Paracetamol. This multi-mechanism approach ensures a consolidated intervention against acute, general discomfort by addressing analgesic, antipyretic, and anti-inflammatory principles simultaneously.

Regulatory References

What side effects are possible with Tomapyrin?

Official Safety Profile and Adverse Reactions

The safety profile for this combination medicine is officially documented by regulatory authorities, with potential adverse effects grouped by frequency and the body system affected (System-Organ Class or SOC).

Adverse Reaction Categories

Classification	Examples of Reactions (Regulatory Documents)
Common	Nervousness, Abdominal pain, Dyspepsia, Nausea, Insomnia (related to Caffeine)
Uncommon	Vomiting, Dizziness, Palpitations, Hypersensitivity reactions (e.g., skin rash)
Rare	Severe gastrointestinal bleeding, Thrombocytopenia (low platelet count), Severe skin reactions, Tinnitus (ringing in the ears)

These reactions primarily affect the Gastrointestinal and Nervous Systems, with other systems, including the Hepatobiliary and Immune Systems, also officially listed in the safety data.

Serious Safety Considerations

Regulatory documents explicitly list several clinically significant risks. These include the potential for Severe Gastrointestinal Hemorrhage and Perforation associated with the NSAID component, and the risk of Acute Liver Failure linked to the Paracetamol component, particularly in cases of misuse or overdose. The risk of Reye's Syndrome is a documented constraint regarding the administration of the Acetylsalicylic acid component to children and adolescents recovering from viral illnesses with fever.

Population and Duration-Related Safety

Specific safety statements exist for defined populations. Older adults are noted to have an increased risk for serious gastrointestinal adverse events. Furthermore, regulatory labeling restricts use in patients with pre-existing conditions such as severe hepatic or renal impairment or active peptic ulcer disease. The risk of Medication Overuse Headache is explicitly documented when the medicine is used for 10 or more days per month, linking safety to the duration of exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose of Tomapyrin requires immediate medical attention. Official regulatory guidance emphasizes that the primary concern relates to the Paracetamol component, which carries a documented risk of severe liver damage.

Documented Manifestations and Outcomes

Overdose exposure can lead to serious, life-threatening outcomes, including liver failure. In the most severe cases, regulatory documents note that this can require a liver transplant or potentially result in death. Physiological disturbances, such as metabolic acidosis, may also occur, which requires close clinical monitoring.

Required Actions and Risk Factors

Regulators mandate a strong warning against taking any other Paracetamol-containing products concurrently with this medicine, as this significantly increases the cumulative risk of severe overdose. Close clinical monitoring is essential following any suspected ingestion, and specific laboratory tests, such as the measurement of urinary 5-oxoproline, may be required. Certain individuals face a heightened risk of severe toxicity: patients with underlying liver disease and those with glutathione depleted states are noted in official labeling as having an increased susceptibility to toxicity and complications. Immediate medical evaluation is required if an overdose is suspected under any circumstance.

Therapeutic Uses of Tomapyrin

What Tomapyrin Treats: Main Uses and Benefits

Tomapyrin is commonly used for symptomatic relief across several key domains, with a strong focus on managing acute pain and systemic discomfort. This combination is applied in situations involving certain distressing symptoms, including acute headaches and general aches.

Acute and Episodic Discomfort

The combination analgesic is commonly used for the management of acute migraine attacks and severe tension headaches, which are conditions characterized by periods of heightened symptoms. It is also relevant in addressing localized discomfort such as menstrual cramps (dysmenorrhoea), toothache, and general muscular aches. The medication is further used in settings marked by temporary physiological imbalance, specifically for feverishness and the associated aches and fatigue of colds and flu-like symptoms. This supportive relief contributes to easing the overall symptom load during difficult episodes.

“Applied in contexts where additional symptomatic support is needed, this combination supports patients during episodes of heightened discomfort.”

Quick Fact: Relief for Acute Pain
Key Domain	Acute Headache Disorders (Migraine & Tension Type)
General Relief	Fever and accompanying Aches/Fatigue
Other Relief Areas	Toothache, Muscular Aches, Menstrual Cramps

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Who can and cannot use Tomapyrin?

Tomapyrin, a combination drug containing Acetylsalicylic acid (ASA), Paracetamol, and Caffeine, is intended for use in the general population not presenting with specific contraindications or restrictions.

Eligibility Classification

Populations

Use is Contraindicated (Prohibited)

Patients with known hypersensitivity/allergy to ASA, Paracetamol, Caffeine, or other Salicylates/NSAIDs; active or recurrent gastrointestinal ulcers, bleeding, or perforation; severe impairment of liver, kidney, or heart function; pre-existing blood coagulation disorders; or glucose-6-phosphate dehydrogenase deficiency. Use is also prohibited in the last trimester of pregnancy and in children under 12 years.

Use Requires Special Consideration/Caution

Individuals with chronic or recurrent stomach problems, mild to moderate liver or kidney impairment, heart muscle weakness, chronic low blood pressure, bronchial asthma, or other allergic conditions. Use is restricted in patients with chronically heavy alcohol intake or those who are older/low body weight.

The medicine should not be used for more than three to four days for pain or three days for fever without consulting a healthcare provider. Its use is generally allowed for adults and adolescents from 12 years of age, provided none of the contraindications are present.

What should I know about interactions with other medicines?

Official Interactions with other medicines and products

This section outlines interactions for Tomapyrin (Acetylsalicylic acid, Paracetamol, Caffeine) as documented in regulatory labeling. The information describes how the drug is documented to interact with other substances or classes, focusing strictly on official interaction statements and constraints.

Interaction Type	Interacting Agent(s) or Category	Official Documented Outcome
Contraindicated Combinations	Other Acetaminophen-containing products	Prohibited co-administration due to the risk of severe liver toxicity.
	Other NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)	Co-use is restricted due to the heightened risk of serious gastrointestinal events.
Pharmacodynamic Risk	Anticoagulants and Antiplatelet Agents	Documented increased risk of bleeding.
	Antihypertensives (e.g., Diuretics, ACE Inhibitors)	The ASA component may officially reduce the therapeutic effect.
Metabolic Risk/Altered Clearance	Liver Enzyme Inducers (e.g., Rifampicin, Antiepileptics)	Documented increased risk of hepatotoxicity from the Paracetamol component.
	Gyrase Inhibitors (Quinolone Carboxylic Acid Type)	Documented to delay the systemic elimination of the Caffeine component.

Specific Constraints and Timing Rules

Busulfan: Regulatory labeling recommends avoiding or limiting the administration of the Paracetamol component for 72 hours before and during treatment with Busulfan due to documented concerns of reduced clearance.
Alcohol/Herbal Products: Consumption of Alcohol is associated with an officially documented increased risk of gastrointestinal bleeding and severe liver damage. Co-use with enzyme-inducing herbal supplements, such as St. John's Wort, is documented to carry a heightened risk of liver damage.
Population Notes: Concomitant use with certain Antihypertensives in elderly, volume-depleted, or renal-impaired patients may result in documented deterioration of renal function.

Regulatory documentation defines this interaction profile by highlighting additive pharmacological risks (e.g., bleeding and GI toxicity) and metabolic hazards (e.g., enzyme-induced liver risk) across its three components. The profile mandates specific dose separation requirements for cytotoxic agents and restricts co-administration with products containing identical ingredients.

Mechanism of Action

How Tomapyrin Works

Tomapyrin operates through multiple mechanistic domains that modulate key physiological pathways rather than solely via a singular pathway. The drug's overall profile is shaped by its ability to engage both chemical-signaling and neural-vascular domains.

Action on Chemical Messengers (Prostaglandins)

The primary mechanism involves the irreversible inhibition of Cyclooxygenase (COX) enzymes in both the central nervous system and peripheral tissues. By blocking COX, Tomapyrin interrupts the synthesis of prostaglandins and thromboxanes. This molecular action modulates signal transduction at the site of mediator synthesis and alters thermoregulatory set-point activity.

Modulation of Central Signaling and Vascular Tone

The second domain affects neural pathways through interaction with specific central nervous system receptors (e.g., serotonin 5 HT1B/1D) and modulation of alpha-Adrenergic signaling. This engagement affects nociceptive signal processing and directly modulates the tone of certain cranial blood vessels. This results in the modulation of the central threshold for nociceptive signal processing and influences localized blood flow.

Influence on Platelet Function

Tomapyrin's mechanism also affects the hemostatic system via the sustained inhibition of Thromboxane A2 ( TXA2) production within circulating platelets. This blockade reduces platelet aggregation, resulting in the alteration of platelet aggregation kinetics.

Dosage and Administration Information

Tomapyrin is formulated as an oral solid dosage form (tablet or caplet), and its administration follows established protocols. The standard single dose for adults is two tablets, which provides 500 mg of Paracetamol (Acetaminophen), 500 mg of Acetylsalicylic acid (ASA), and 130 mg of Caffeine.

The frequency of administration is restricted to as needed for acute symptoms, with a required minimum interval of six hours between doses. Under no circumstances should the total intake exceed eight tablets within a 24-hour duration.

Administration Conditions and Duration

The use of this medication is specifically defined as episodic and short-term. For conditions like headache, the medication is not intended for use on 10 or more days per month to adhere to recognized procedural limits for combination analgesics.

Regarding proper ingestion, the drug must be taken orally with a full glass of water. A critical instruction is the prohibition of concurrent use with any other medicine containing Paracetamol (Acetaminophen) to prevent accidental component overdose. Furthermore, due to the Caffeine content in the formulation, it is recommended to limit the consumption of caffeine from dietary sources (such as coffee or tea) during the period of administration.

For age-based application, the medicine is not approved for children under 12 years of age, but the standard adult dosing schedule applies to patients 12 years and older.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tomapyrin

The research describing Tomapyrin (a combination of Acetylsalicylic acid, Paracetamol, and Caffeine) focuses on how this specific formulation was evaluated in studies of acute physical discomfort and pain. The evidence is derived primarily from high-quality clinical research, such as Randomized Controlled Trials (RCTs), and systematic reviews that compile and analyze findings from these multiple studies. The summaries below describe what types of research have been conducted and what patterns were reported in the study findings, without offering guidance on use.

Evidence for Use in Acute Migraine Attacks

Research for this combination analgesic was applied in studies examining patient-reported experiences of conditions associated with acute or disruptive episodes, specifically migraine. The core evidence consists of short-term, single-dose RCTs. The main outcomes researchers monitored were how quickly participants achieved significant headache relief or became pain-free at set observation points. Observed patterns in the studies described measurements of these short-term endpoints that were recorded faster for the triple combination compared to the control groups. Evidence is highly focused on research exploring short-term symptom changes during a single event. Long-term effects are not fully established.

Evidence for Use in Episodic Tension-Type Headache

Studies examined participants with moderate-to-severe pain during a single episode of tension-type headache. The outcomes tracked included patient-reported scores on pain intensity and total pain reduction over a set period. Data show patterns related to the speed of initial pain reduction; the triple combination group was observed to have records of shorter times to initial pain reduction. Follow-up durations were limited in these studies, meaning they primarily provide information about the management of a single acute episode. Evidence is limited for the long-term use of this medicine.

Gaps in Research and Areas of Uncertainty

The main research limitation frames include: Follow-up durations were limited (focus on acute relief only). Specific trials are limited (for every specific general pain scenario). Chronic Conditions: There is a scarcity of data regarding the use of this medicine in the management of chronic pain disorders. Subgroup findings are uncertain: Data for specific subgroups, such as older adults or patients with certain co-occurring medical conditions, remain insufficient.

Key Studies & References

Aspirin, Acetaminophen, and Caffeine Tablet: Official Labeling Data (NIH DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Tomapyrin (FAQ)

Q: Are there any specific foods or drinks that should be avoided while taking Tomapyrin?

Official product information suggests limiting the consumption of dietary caffeine, such as coffee or tea. This is due to the existing caffeine content in the drug formulation. Furthermore, regulatory documents note that consuming alcohol is associated with an officially documented increased risk of gastrointestinal bleeding and severe liver damage.

Q: Is Tomapyrin known to cause stomach upset?

Regulatory documents list several gastrointestinal issues as adverse reactions. Abdominal pain and dyspepsia (which is a form of indigestion) are classified as common reactions in the official safety profile. The classification of these reactions indicates that some individuals may experience gastrointestinal discomfort.

Q: Can I take Tomapyrin if I have a history of ulcers or stomach bleeding?

Official product labeling strictly prohibits the use of the drug in patients with active or recurrent gastrointestinal ulcers, bleeding, or perforation. For patients with a history of these conditions where they are not currently active, official documents classify use as requiring special consideration or caution.

Q: Why does the packaging for Tomapyrin mention a warning for people with certain heart conditions?

Official warnings and safety documentation describe specific constraints for patients with heart issues. The medicine is strictly contraindicated (prohibited) for those with severe impairment of heart function. Additionally, individuals with pre-existing conditions like heart muscle weakness are listed as requiring special consideration for use.

Q: Does Tomapyrin interact with common over-the-counter cold medicines?

Regulatory documentation prohibits the co-administration of Tomapyrin with any other product that contains either Acetaminophen or any other Nonsteroidal Anti-Inflammatory Drug (NSAID). Co-administration with these products is officially restricted due to the heightened risk of adverse events.

Q: If I have a history of kidney problems, is Tomapyrin strictly off-limits?

The drug is strictly prohibited in cases of severe impairment of kidney function. For individuals with mild to moderate kidney impairment, official documents state that use is classified as requiring special consideration and caution.

Q: Is it okay to stop taking Tomapyrin suddenly?

Official documentation emphasizes that the intended use is episodic and short-term, which defines the scope of its use. The safety profile explicitly documents the risk of developing a Medication Overuse Headache when the drug is used frequently (defined as 10 or more days per month).

Q: Is Tomapyrin a scheduled or controlled substance?

Regulatory documents classify Tomapyrin as a Combination Analgesic, Antipyretic, and NSAID Derivative. This classification indicates that the medicine is a non-opioid analgesic combination and is not listed as a controlled substance.

Q: How quickly do most people typically start feeling the effects of Tomapyrin?

Research studies focused on outcomes such as the speed of initial pain reduction. Observed patterns recorded shorter times to initial relief compared to control groups, suggesting a rapid commencement of measurable effects. Evidence is highly focused on research exploring short-term symptom changes during a single event.

Q: Can Tomapyrin affect my ability to drive or operate machinery?

The official safety profile lists adverse reactions that can affect the central nervous system, such as dizziness and nervousness. Individuals who experience these reactions should be mindful that they may indirectly affect abilities requiring full attention or coordination.

Q: Is it possible to take Tomapyrin if I am already on blood pressure medicine?

Regulatory documentation notes a potential pharmacodynamic risk with certain blood pressure medicines. Specifically, the Acetylsalicylic acid (ASA) component may officially reduce the therapeutic effect of certain antihypertensives, such as Diuretics or ACE Inhibitors.

Q: Does Tomapyrin have any known impact on liver function?

Regulatory documents note impacts on the liver. Severe impairment of liver function is listed as a contraindication. Furthermore, the Paracetamol component is linked to the risk of Acute Liver Failure in cases of misuse or overdose.

Q: Are there any skin-related side effects linked to Tomapyrin use?

The official safety profile includes several skin-related reactions. Hypersensitivity reactions, such as a skin rash, are documented as uncommon. More serious, though rare, safety statements include the potential for Severe skin reactions.

Q: Is it mandatory to take Tomapyrin with food?

Official instructions state the drug must be taken orally with a full glass of water. There is no official mandatory instruction that the medicine must be taken with food for it to work correctly.

Q: Are there any genetic factors that might affect how Tomapyrin works for someone?

Yes, official documentation lists Glucose-6-phosphate dehydrogenase (G6PD) deficiency as an explicit contraindication for the use of Tomapyrin. G6PD deficiency is a genetic condition that affects eligibility for the drug.

Q: Is the active ingredient in Tomapyrin a naturally derived compound?

According to the official Quick Facts, the medicine is described as Synthetic (Chemically Derived). It is a product synthesized from chemicals, not extracted directly from a natural source.

Q: Is Tomapyrin known to interact with caffeine?

Since Tomapyrin already contains caffeine, official instructions direct individuals to limit their consumption of additional dietary caffeine (such as coffee, tea, or soda) during the period of administration.

Q: Are there specific patient groups that had the best outcomes in clinical trials for Tomapyrin?

Official research summaries state that the evidence is primarily focused on short-term acute relief in the general study population. The documentation explicitly notes that data for specific subgroups (like older adults or patients with other conditions) remain insufficient.

Q: Can Tomapyrin be taken on an empty stomach?

Official instructions state the drug must be taken orally with a full glass of water. Since the official instruction is to take the medicine orally with water, and not mandatorily with food, the product information does not restrict taking it without a meal.

Q: Is Tomapyrin safe for older adults (seniors)?

Regulatory documentation notes that while the drug is generally available to adults, older adults are specifically listed as having an officially documented increased risk for serious gastrointestinal adverse events compared to younger adults.

How should Tomapyrin be stored and disposed of?

How to Store and Dispose of Tomapyrin

Official regulatory labeling dictates specific conditions for storing and disposing of this medicine.

Requirement Domain	Official Storage and Protection Constraints
Temperature & Environment	Store at controlled room temperature, typically between 20°C and 25°C. The product must be protected from freezing, excess heat, and moisture.
Container & Stability	Keep Tomapyrin in the original container and ensure the safety cap is tightly closed to protect the tablets from moisture and environmental degradation.
Child Safety	Mandatory instruction is to keep the medicine out of the sight and reach of children in a secured location.

For disposal, unused or expired Tomapyrin should not be thrown into household trash or flushed down the toilet, unless explicitly authorized. The preferred method is to utilize an official medicine take-back program or follow the FDA-recommended procedure of mixing the tablets with an unappealing substance, sealing the mixture, and discarding it.

Tomapyrin